RAREHealthcareMid-Cap
Ultragenyx Pharmaceutical Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Ultragenyx Pharmaceutical Inc. (RARE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are RARE insiders buying or selling?
Ultragenyx Pharmaceutical Inc. insiders reported 1 open-market buys ($218.2K) and 188 sells ($86.9M) across 189 Form 4 filings — a net selling position of $86.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 6, 2026)
Total Form 4 filings
189
SEC EDGAR
Insider filers
17
Insider buys (1)
$218.2K
Insider sells (188)
$86.9M
Insider sentiment
Net sellingNet insider flow of $86.7M in net selling.
Recent RARE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $33.13 | $155.6K |
| Jun 15, 2026 | Corazon (Corsee) D. Sanders | Director | Sale | 2.0K | $25.05 | $50.1K |
| Jun 15, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 1.9K | $24.62 | $46.8K |
| Jun 1, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $23.77 | $110.6K |
| May 18, 2026 | Shehnaaz Suliman | Director | Sale | 5.7K | $25.12 | $144.2K |
| May 6, 2026 | Eric Crombez | EVP and Chief Medical Officer | Sale | 344 | $24.96 | $8.6K |
| May 4, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $24.90 | $116.6K |
| Apr 2, 2026 | Howard Horn | Chief Financial Officer | Sale | 4.7K | $20.97 | $98.2K |
| Mar 10, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 9.5K | $21.87 | $208.3K |
| Mar 4, 2026 | John Richard Pinion | EVP, Chief Quality Operations Officer | Sale | 10.0K | $22.80 | $228.7K |
| Mar 4, 2026 | Erik Harris | EVP & Chief Commercial Officer | Sale | 10.5K | $22.80 | $240.3K |
| Mar 4, 2026 | Emil D Kakkis | President & CEO | Sale | 54.4K | $22.80 | $1.2M |
| Mar 3, 2026 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 8.1K | $22.80 | $185.5K |
| Mar 3, 2026 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 1.6K | $22.80 | $37.2K |
| Mar 3, 2026 | Howard Horn | Chief Financial Officer | Sale | 10.0K | $22.65 | $227.5K |
| Mar 3, 2026 | Eric Crombez | EVP and Chief Medical Officer | Sale | 7.0K | $22.80 | $160.3K |
| Feb 3, 2026 | Howard Horn | Chief Financial Officer | Sale | 3.1K | $23.56 | $72.1K |
| Dec 30, 2025 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 85 | $34.38 | $2.9K |
| Dec 11, 2025 | Howard Horn | Chief Financial Officer | Sale | 3.1K | $36.38 | $112.1K |
| Oct 14, 2025 | Howard Horn | Chief Financial Officer | Sale | 7.9K | $31.51 | $250.3K |
| Sep 19, 2025 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 64 | $29.17 | $1.9K |
| Sep 12, 2025 | Karah Herdman Parschauer | EVP and Chief Legal Officer | Sale | 2.5K | $31.17 | $76.4K |
| Sep 8, 2025 | Theodore Alan Huizenga | SVP, Chief Accounting Officer | Sale | 84 | $31.39 | $2.6K |
| Jun 23, 2025 | Corazon (Corsee) D. Sanders | Director | Sale | 2.4K | $37.39 | $89.9K |
| May 5, 2025 | Eric Crombez | EVP and Chief Medical Officer | Sale | 762 | $37.93 | $28.9K |
Showing the 25 most recent of 189 Form 4 filings for Ultragenyx Pharmaceutical Inc..
Most active RARE insiders
- Karah Herdman Parschauer32 filings
- Theodore Alan Huizenga28 filings
- Emil D Kakkis18 filings
- Erik Harris16 filings
- John Richard Pinion12 filings
Ask anything about RARE insider activity
Use Trabud's AI agent to query Ultragenyx Pharmaceutical Inc.'s Form 4 history in plain English — "Show me RARE CEO purchases this year" or compare it against any other ticker.
Open the AI agentRARE insider trading FAQ
Are Ultragenyx Pharmaceutical Inc. insiders buying or selling?
Across 189 SEC Form 4 filings, Ultragenyx Pharmaceutical Inc. (RARE) insiders reported 1 open-market purchases totaling $218.2K and 188 sales totaling $86.9M. That is a net selling position of $86.7M.
How many insiders trade RARE stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Ultragenyx Pharmaceutical Inc.. The most recent filing was accepted on Jul 6, 2026.
Where does Trabud get RARE insider trading data?
All RARE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.